Related Experiment Video
Updated: Jan 10, 2026

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
Published on: July 19, 2018
[Third-line therapy in a patient with recurrent colon cancer undergoing hemodialysis]
Masaki Matsuda1, Yasuji Seyama, Kentaro Inada
1Dept. of Surgery, Tokyo Metropolitan Bokutoh Hospital.
Abstract:
A 68-year-old man undergoing hemodialysis (HD) was diagnosed with recurrence of colon cancer and liver metastasis. He was treated with oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX4), folinic acid, 5-fluorouracil and irinotecan (FOLFIRI), FOLFIRI+bevacizumab (BV), and cetuximab+irinotecan (CPT-11) as third-line therapy. Each drug was adequately reduced over time, but cetuximab was administered at the standard dose. The patient died of methicillin-resistant Staphylococcus aureus (MRSA) meningitis during the course of cetuximab+CPT-11 therapy, but there was no relation between the meningitis and the therapy. Therefore, each regimen can be safely performed, and cetuximab+CPT-11 therapy showed a significant anti-tumor effect and hence may be an effective regimen.
Related Concept Videos
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Hemodialysis III: Nursing Management
Hemodialysis II: Procedure and Complications
Hemodialysis I: Introduction
Peritoneal Dialysis III: Nursing Management

